begelomab   Click here for help

GtoPdb Ligand ID: 8691

Synonyms: Begendina&rg; (proprietary name) | BT 5/9 | SAND 26
Immunopharmacology Ligand
Compound class: Antibody
Comment: Begelomab is an investigational murine monoclonal antibody targeting DPP4 (dipeptidyl-peptidase 4, a.k.a. CD26 T cell antigen).
Peptide sequence and structural information for begelomab is available from its IMGT/mAb-DB entry.
A search of patent literature reveals that the heavy chain variable region CDRs and light chain variable region CDRs of begelomab match sequences of anti-CD26 antibodies disclosed in FIG 2a of patent EP2767549 A1 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Begelomab reached Phase clinical trial as a potential therapy for steroid-resistant acute graft versus host disease (GvHD).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CD26 (DPP4) is a marker of T cell activation and is an important regulator of inflammation. CD26+ cells accumulate in the organs of patients with GvHD. Administration of an anti-CD26 antibody has been reported to decrease GvHD symptoms in a mouse model [2], making CD26 a novel target for therapeutic intervention in this disease and possibly in autoimmune diseases.